Alere NMP22 BladderChek Test

GUDID 10811877010774

The Alere NMP22 BladderChek Test is an in vitro immunoassay intended for the qualitative detection of the nuclear mitotic apparatus protein (NuMA) in urine of persons with risk factors or symptoms of bladder cancer or with a history of bladder cancer.

Alere Scarborough, Inc.

Nuclear matrix protein 22 IVD, kit, rapid ICT, clinical

• Primary Device ID: 10811877010774
• NIH Device Record Key: a06e148d-3c07-4ce8-b764-c72f7aa35ae4
• Commercial Distribution Discontinuation: 2015-10-31
• Commercial Distribution Status: Not in Commercial Distribution
• Brand Name: Alere NMP22 BladderChek Test
• Version Model Number: D1300
• Company DUNS: 154148498
• Company Name: Alere Scarborough, Inc.
• Device Count: 1
• DM Exempt: false
• Pre-market Exempt: false
• MRI Safety Status: Labeling does not contain MRI Safety Information
• Human Cell/Tissue Product: false
• Device Kit: true
• Device Combination Product: false
• Single Use: true
• Lot Batch: true
• Serial Number: false
• Manufacturing Date: false
• Expiration Date: true
• Donation Id Number: false
• Contains Natural Rubber Latex: false
• Labeled No Natural Rubber Latex: false
• RX Perscription: false
• OTC Over-The-Counter: false

Device Identifiers

Device Issuing Agency	Device ID
GS1	10811877010774 [Primary]

FDA Product Code

• NAH: System, Test, Tumor Marker, For Detection Of Bladder Cancer

Sterilization

• Steralize Prior To Use: false
• Device Is Sterile: false

Device Entry Metadata

• Public Version Status: Update
• Device Record Status: Published
• Public Version Number: 3
• Public Version Date: 2022-06-10
• Device Publish Date: 2014-09-01

On-Brand Devices [Alere NMP22 BladderChek Test]

• 10811877010774: The Alere NMP22 BladderChek Test is an in vitro immunoassay intended for the qualitative detecti
• 10811877010569: The Alere NMP22 BladderChek Test is an in vitro immunoassay intended for the qualitative detecti